CliffBio
small molecule

LASTACAFT

ALCAFTADINE

Loss of exclusivityDecember 2027latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameLASTACAFT
Active ingredientALCAFTADINE
Strength0.25%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 2010
Marketing statusOTC

Listed patents

PatentExpiresType
8664215December 2027use U-3267
10617695March 2027product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LASTACAFT patent cliff — loss of exclusivity December 2027 | CliffBio